Zhao Wu

机构：Hubei University of Arts and Science, China Telecom (China), China Telecom · ORCID：0000-0002-3941-3625

发表论文 46 篇 · 总被引 3006 次 · h-index 17

代表论文

• Houttuynia cordata Thunb: An Ethnopharmacological Review (2021 · Frontiers in Pharmacology · 被引 125)
• Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID‐19 (2020 · Journal of Medical Virology · 被引 123)
• Flavonoids on diabetic nephropathy: advances and therapeutic opportunities (2021 · Chinese Medicine · 被引 120)
• Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size (2020 · Biomedicine & Pharmacotherapy · 被引 107)
• Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial (2021 · International Immunopharmacology · 被引 43)
• Significant histological changes and satisfying antiviral efficacy in chronic hepatitis B virus infection patients with normal alanine aminotransferase. Antiviral therapy decision in chronic HBV patients with normal ALT (2020 · Clinics and Research in Hepatology and Gastroenterology · 被引 20)